Search

everythinglearnresearchcommunity

for

Search:↓

Biologics and targeted therapies could improve treatment for children with certain chronic skin conditions.

Abrocitinib, a JAK inhibitor, may help treat atopic dermatitis and alopecia universalis together.

Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.

Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.

Tofacitinib helped regrow hair in patients with alopecia, with few side effects.

Tofacitinib is effective and safe for treating severe alopecia areata and related conditions.

A JAK inhibitor improved both severe hair loss and chronic skin disease in one patient.

Abrocitinib may help treat alopecia areata effectively with mild side effects.

Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.

Abrocitinib helped a 14-year-old girl with severe alopecia areata regrow her hair significantly.

Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.

A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.

Axitinib treatment turned a man's grey hair back to black.

Tofacitinib citrate improved nail dystrophy and pain in patients with alopecia universalis without causing side effects.

Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.

Ivarmacitinib effectively regrows hair in severe alopecia areata.

A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.

Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.

Tofacitinib may help treat severe childhood alopecia areata, but risks require careful consideration.

The drug showed promise in treating renal cell carcinoma with manageable side effects.

Abrocitinib effectively treats severe alopecia areata with significant improvement and no side effects.

Dacomitinib can cause nail and skin issues, but these can be managed without stopping the drug.

Tofacitinib helps improve skin conditions in people with Down syndrome, especially alopecia areata.

Tofacitinib, a JAK inhibitor, improved hair regrowth in most patients with severe alopecia areata and had minimal side effects.

Ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata.

Tofacitinib may help regrow hair in alopecia areata patients.

Abrocitinib at 100 mg and 200 mg daily may significantly improve moderate-to-severe atopic dermatitis in patients 12 years and older.

Tofacitinib treatment for hair loss may worsen acne.

Tofacitinib helped some young children with severe hair loss grow their hair back without bad side effects.

Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.